RIPK3 and Glucose intolerance: The findings suggest that targeting Mlkl or Ripk3 could provide therapeutic benefits in reducing age-related liver inflammation and pathology; however, Mlkl is a better candidate based on the adverse effects of Ripk3 deletion on glucose intolerance and lifespan.